Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Innate Pharma SA ( (FR:IPH) ) is now available.
Innate Pharma SA reported its first half 2025 business update and financial results, highlighting significant progress in its clinical pipeline. The company is advancing its IPH4502 Nectin-4 ADC through Phase 1 trials and preparing for a Phase 3 trial of lacutamab following its FDA Breakthrough Therapy Designation. Strategic priorities include focusing on high-value clinical assets and streamlining operations, with a planned 30% reduction in staffing. A €15 million equity investment by Sanofi and a strong cash position of €70.4 million as of June 30, 2025, support Innate’s continued development efforts.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma SA is a biotechnology company based in Marseille, France, specializing in the development of immunotherapies for cancer treatment. The company focuses on antibody-based therapeutics, including Antibody Drug Conjugates (ADCs) and NK cell engagers, with a strategic emphasis on its clinical assets such as IPH4502, lacutamab, and monalizumab.
Average Trading Volume: 163,077
Technical Sentiment Signal: Sell
Current Market Cap: €167.6M
For detailed information about IPH stock, go to TipRanks’ Stock Analysis page.